Impact of high-fat diet on liver genes expression profiles in mice model of nonalcoholic fatty liver disease

Environmental Toxicology and Pharmacology

Volumn 45, Issue , 2016, Pages 52-62

  Wang, Chunhua ^a,b   Tao, Qimeng ^a,c   Wang, Xinghe ^a   Wang, Xiurong ^c   Zhang, Xiuying ^a  

^a NORTHEAST AGRICULTURAL UNIVERSITY   (China)

^b MUDANJIANG NORMAL UNIVERSITY   (China)

^c Harbin Veterinary Research Institute   (China)

Author keywords

Cytochrome P450; Drug metabolizing enzymes; Liver gene expression; Nonalcoholic fatty liver disease

Indexed keywords

OXIDOREDUCTASE; TRANSCRIPTOME; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASNS GENE; CONTROLLED STUDY; CYP17A1 GENE; CYP2C54 GENE; CYP2C55 GENE; CYP2E1 GENE; CYP3A41A GENE; CYP4F14 GENE; CYP51 GENE; CYP7A1 GENE; CYP8B1 GENE; DOWN REGULATION; DRUG METABOLISM; ENZYME ACTIVITY; GENE; GENE EXPRESSION PROFILING; GENETIC VARIATION; GSTAALPHA 1 GENE; GSTM2 GENE; GSTT3 GENE; INFLAMMATION; LIPID DIET; LIPID METABOLISM; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEIC ACID METABOLISM; OXIDATIVE STRESS; PAST1 GENE; PRIORITY JOURNAL; RNA ANALYSIS; SULT1E1 GENE; SULT3A1 GENE; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; LIVER; METABOLISM; PATHOLOGY;

ANIMALS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; LIVER; MALE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; RNA, MESSENGER; TRANSCRIPTOME;

EID: 84973352304     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2016.05.014     Document Type: Article

References (32)

1. Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., Maratos-Flier E. Hepatic fibroblastgrowth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007, 5:426-437.
2. Balasubramanian M.N., Butterworth E.A., Kilberg M.S. Asparagine synthetase: regulation by cell stress and involvement in tumor biology. Am. J. Physiol. Endocrinol. Metab. 2013, 304:789-799.
3. Bardowell S.A., Duan F., Manor D., Swanson J.E., Parker R.S. Disruption of mouse cytochrome p450 4f14 (Cyp4f14 gene) causes severe perturbations in vitamin E metabolism. J. Bio. Chem. 2012, 287:26077-26086.
4. Brunt E.M. Pathology of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:195-203.
5. Buechler C., Weiss T.S. Does hepatic steatosis affect drug metabolizing enzymes in the liver?. Curr. Drug Metab. 2011, 12:24-34.
6. Clark J.M. The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol. 2006, 40:S5-S10.
7. Day C.P., James O.F. Steatohepatitis: a tale of two hits?. Gastroenterology 1998, 114:842-845.
8. Fisher C.D., Lickteig A.J., Augustine L.M., Oude-Elferink R.P., Besselsen D.G., Erickson R.P., Cherrington N.J. Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur. J. Pharmacol. 2009, 613:119-127.
9. Gómez-Lechón M.J., Jover R., Donato M.T. Cytochrome P450 and steatosis. Curr. Drug Metab. 2009, 10:692-699.
10. Ishida H., Yamashita C., Kuruta Y., Yoshida Y., Noshiro M. Insulin is a dominant suppressor of sterol 12a-hy- droxylase P450 (CYP8B) expression in rat liver: possible role of insulin in Orcadian rhythm of CYP8R. J. Biochem. 2000, 127:57-64.
11. Kirpich I.A., Gobejishvili L.N., Bon Homme M., Waigel S., Cave M., Arteel G., Barve S.S., Mcclain C., Deaciuc I.V. Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease. J. Nutr. Biochem. 2011, 22:38-45.
12. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., Ferrell L.D., Liu Y.C., Torbenson M.S., Arida A.U., Yeh M., McCullough A.J., Sanyal A.J. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
13. Kohjima M., Enjoji M., Higuchi N., Kato M., Kotoh K., Yoshimoto T., Fujino T., Yada M., Yada R., Harada N., Takayanagi R., Nakamuta M. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int. J. Mol. Med. 2007, 20:351-358.
14. Li P., Robertson T.A., Thorling C.A., Zhang Q., Fletcher L.M., Crawford D.H., Roberts M.S. Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Drug Metab. Dispos. 2011, 39:571-579.
15. Li Y., Jadhav K., Zhang Y. Bile acid receptors in non-alcoholic fatty liver disease. Biochem. Pharmacol. 2013, 86:1517-1524.
16. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., Forlani G., Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 1999, 107:450-455.
17. Ogawa Y., Kurosu H., Yamamoto M., Nandi A., Rosenblatt K.P., Goetz R., Eliseenkova A.V., Mohammadi M., Kuro-o M. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:7432-7437.
18. Osabe M., Sugatani J., Fukuyama T., Ikushiro S., Ikari A., Miwa M. Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator-activated receptor alpha in male rats fed a high-fat and high-sucrose diet. Drug Metab. Dispos. 2008, 36:294-302.
19. Porter T.D., Coon M.J. Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J. Biol. Chem. 1991, 266:13469-13472.
20. Rao M.S., Reddy J.K. PPARalpha in the pathogenesis of fatty liver disease. Hepatology 2004, 40:783-786.
21. Reddy J.K., Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 2001, 21:193-230.
22. Shi X.F., Sun M., Liu H.B., Yao Y.W., Song Y. Long Non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013, 339:159-166.
23. Spahis S., Alvarez F., Dubois J., Ahmed N., Peretti N., Levy E. Plasma fatty acid composition in French-Canadian children with non-alcoholic fatty liver disease: effect of n-3 PUFA supplementation. Prostaglandins Leukot. Essent. Fatty Acids 2015, 99:25-34.
24. Tan C.T.H., Crawford D.H.G., Jaskowski L.A., Subramaniam V.N., Clouston A.D., Crane D.I., Bridle K.R., Anderson G.J., Fletcher L.M. Excess iron modulates endoplasmic reticulum stress-associated pathways in a mouse model of alcohol and high-fat diet-induced liver injury. Lab. Invest. 2013, 93:1295-1312.
25. Tarantino G., Conca P., Basile V., Gentile A., Capone D., Polichetti G., Leo E. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol. Res. 2007, 37:410-415.
26. Tarantino G., Di Minno M.N., Capone D. Drug-induced liver injury: is it somehow foreseeable?. World J. Gastroenterol. 2009, 15:2817-2833.
27. Timm D.E., Baker L.J., Mueller H., Zidek L., Novotny M.V. Structural basis of pheromone binding to mouse major urinary protein (MUP-I). Protein Sci. 2001, 10:997-1004.
28. Tiniakos D.G., Vos M.B., Brunt E.M. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu. Rev. Pathol. Mech. 2010, 5:145-171.
29. Yan H., Xia M., Chang X., Xu Q., Bian H., Zeng M., Rao S., Yao X., Tu Y., Jia W., Gao X. Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study. PLoS One 2001, 6:24895.
30. Yeh M.M., Brunt E.M. Pathology of nonalcoholic fatty liver disease. Am. J. Clin. Pathol. 2007, 128:837-847.
31. Zhang W.V., Ramzan I., Murray M. Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis. J. Pharmacol. Exp. Ther. 2007, 322:770-777.
32. Zhang B., Dong L.W., Tan Y.X., Zhang J., Pan Y.F., Yang C. Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma. Br. J. Cancer 2013, 109:14-23.